MarketPulse

ovarian cancer

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

IMUNON Sets March 31 Call to Detail 2025 Results, OVATION 3 Trial Progress

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.
IMNNPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ArriVent to Showcase EGFR Inhibitor and Dual-Target ADC at 2026 AACR Meeting

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.
AVBPPhase 3 trialNSCLC
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allarity Therapeutics Secures $20M Funding to Accelerate Stenoparib FDA Path

Allarity Therapeutics secures $20M non-dilutive debt financing to complete stenoparib Phase 2 trial and advance toward FDA approval, extending runway to mid-2028.
ALLRFDA approvaldebt financing
GlobeNewswire Inc.GlobeNewswire Inc.··Pmv Pharmaceuticals, Inc.

PMV Pharma's Rezatapopt Shows Promise, But Cash Clock Ticks Toward 2027

PMV Pharmaceuticals reports 50% response rate for ovarian cancer drug rezatapopt, but faces funding pressure with cash runway extending only to Q2 2027.
PMVPclinical trial resultsorphan drug designation